Hims

Stocks making the biggest moves midday: Expedia, Nvidia, Strategy, Hims & Hers and more

Here are the companies making headlines in midday trading.

Companies with huge datasets can save up to 80% in AI costs by using open-weight models: Hims CEO

Companies with huge datasets can save up to 80% in AI costs by using open-weight models: Hims CEO

Hims & Hers CEO says FTC lawsuit misunderstands how the company works

Hims & Hers CEO Andrew Dudum spoke to CNBC about the FTC's lawsuit against the company, compounded GLP-1 drugs and AI.

Hims & Hers sent users' health data to social media giants despite promising privacy, bombshell FTC lawsuit claims

Hims & Hers stock added to losses after the news and was trading down around 12%.

Hims and Hers shares fall 10% as FTC sues company over data, billing practices

The FTC sued Hims & Hers over alleged health data sharing with Meta and Snap, billing practices and subscription cancellations.

Hims & Hers CEO is plotting new ways to upend traditional health care

Hims & Hers built massive weight-loss markets using telehealth. Peptides, if authorized by the FDA, stand to become a major part of the company's shift to well…

Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance

Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.

Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin Down

Stocks making the biggest moves after hours: Hims & Hers, Gitlab, Cleanspark, Webtoon Entertainment & more

See which stocks are posting big moves after the bell.

Stocks making the biggest moves midday: Intel, AMD, Charter, Hims & Hers, Eli Lilly and more

These are the stocks posting the largest moves in midday trading.

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides

Hims & Hers Health's plan to enter the business of selling peptides is looking a lot more realistic.

Telehealth giant Hims & Hers says its customer support system was hacked

The U.S. telehealth giant says hackers stole customer support ticket data over the course of several days in February.

Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more

These are some of the stocks seeing the largest midday moves.

Stock Market Today: Dow, Nasdaq 100, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike - Hims & Hers In Focus (UPDATED)

Editor's Note: The future prices of benchmark tracking ETFs and the headline were updated in the story. U.S. stock futures fell sharply on Monday following Fri…

Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.

Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute

Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Da…

Hims & Hers' expansion plans - as well as its Super Bowl ad - have investors worried about profits

The wellness platform's results arrived amid heightened legal and regulatory scrutiny over its weight-loss-drug business.

Hims & Hers is spending more than $1 billion in a push to expand globally

Hims & Hers' stock surges as a $1.2 billion deal to buy an Australia-based telehealth company affirms the health-and-wellness company's global ambitions.

Stocks making the biggest moves premarket: Walmart, Hims & Hers, Carvana, Figma & more

These are the stocks posting the largest moves in the premarket.

Hims & Hers stock plunges after weight loss pill pulled amid FDA scrutiny

Stocks for Hims & Hers fell on Monday after the company pulled its $49 weight loss pill that's under FDA scrutiny. Yahoo Finance senior reporter Brooke DiPalma…

Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.

Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk's Wegovy oral we…

Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday - two days after it announced the new dr…

Hims & Hers removes a knock-off weight loss drug days after introducing it

Hims & Hers removes a knock-off weight loss drug days after introducing it

Hims & Hers Withdraws Knockoff Weight-Loss Pill After Regulatory Scrutiny

Federal officials had warned that the new product from the online provider of weight loss drugs might be illegal.

Hims & Hers pulls copycat weight-loss pill after threats of legal action

Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal action.

U.S. signals crackdown on compounded weight-loss drugs; Hims shares tumble

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill

Hims & Hers also said it's selling a cancer-detection test that's featured in its Super Bowl ad, which plays like a commentary on the wealthy's access to bette…